Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Australian Clinical Labs Ltd ( (AU:ACL) ).
Australian Clinical Labs Limited has announced the details for its 2025 Annual General Meeting, including the AGM Notice of Meeting, Proxy Form, Shareholder Question Form, and an Online Guide from Link Market Services. The announcement also includes the release of the company’s 2025 Annual Report, which encompasses the Corporate Governance Statement. This release is significant for stakeholders as it provides insights into the company’s governance and operational strategies, potentially impacting its market positioning and stakeholder engagement.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$3.50 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs (ACL) is a prominent provider of pathology services in Australia. The company operates NATA accredited laboratories that conduct a wide range of pathology tests for various clients, including doctors, specialists, patients, hospitals, and corporate clients. ACL is recognized as one of the largest private hospital pathology businesses in the country, focusing on integrating talented personnel, medical and scientific leadership, and innovative technologies to enhance decision-making and improve patient outcomes.
Average Trading Volume: 909,315
Technical Sentiment Signal: Sell
Current Market Cap: A$489.5M
For an in-depth examination of ACL stock, go to TipRanks’ Overview page.